Peter Paschka
Overview
Explore the profile of Peter Paschka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
7726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schmalbrock L, Dolnik A, Cocciardi S, Strang E, Theis F, Jahn N, et al.
Blood
. 2021 Feb;
137(22):3093-3104.
PMID: 33598693
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival...
12.
Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik V, Paschka P, Kronke J, et al.
Blood
. 2020 Dec;
136(26):3041-3050.
PMID: 33367545
Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1-mutated (NPM1mut) acute myeloid leukemia (AML) and represents a powerful tool to evaluate treatment effects within clinical trials....
13.
Jahn N, Terzer T, Strang E, Dolnik A, Cocciardi S, Panina E, et al.
Blood Adv
. 2020 Dec;
4(24):6342-6352.
PMID: 33351131
Core-binding factor (CBF) acute myeloid leukemia (AML) encompasses AML with inv(16)(p13.1q22) and AML with t(8;21)(q22;q22.1). Despite sharing a common pathogenic mechanism involving rearrangements of the CBF transcriptional complex, there is...
14.
Schlenk R, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik V, et al.
J Clin Oncol
. 2019 Dec;
38(6):623-632.
PMID: 31851556
Purpose: High CD33 expression in acute myeloid leukemia (AML) with mutated provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial...
15.
Meyer T, Jahn N, Lindner S, Rohner L, Dolnik A, Weber D, et al.
Leukemia
. 2019 Oct;
34(2):404-415.
PMID: 31576005
BRCA1/BRCA2-containing complex 3 (BRCC3) is a Lysine 63-specific deubiquitinating enzyme (DUB) involved in inflammasome activity, interferon signaling, and DNA damage repair. Recurrent mutations in BRCC3 have been reported in myelodysplastic...
16.
Rucker F, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik V, et al.
Blood
. 2019 Sep;
134(19):1608-1618.
PMID: 31554635
We performed serial measurable residual disease (MRD) monitoring in bone marrow (BM) and peripheral blood (PB) samples of 155 intensively treated patients with RUNX1-RUNX1T1+ AML, using a qRT-PC-based assay with...
17.
Agrawal M, Schwarz P, Giaimo B, Bedzhov I, Corbacioglu A, Weber D, et al.
Leukemia
. 2019 Aug;
34(2):630-634.
PMID: 31462736
No abstract available.
18.
Rudorf A, Muller T, Klingeberg C, Kreutmair S, Poggio T, Gorantla S, et al.
Blood
. 2019 Jun;
134(4):383-388.
PMID: 31186273
Activating mutations in FMS-like tyrosine kinase receptor-3 (FLT3) and Nucleophosmin-1 (NPM1) are most frequent alterations in acute myeloid leukemia (AML), and are often coincidental. The mutational status of NPM1 has...
19.
Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rucker F, Lux S, Blatte T, et al.
Nat Commun
. 2019 May;
10(1):2031.
PMID: 31048683
Mutations in the nucleophosmin 1 (NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of NPM1 mutated (NPM1) AML, we...
20.
Schlenk R, Weber D, Fiedler W, Salih H, Wulf G, Salwender H, et al.
Blood
. 2018 Dec;
133(8):840-851.
PMID: 30563875
Patients with acute myeloid leukemia (AML) and a internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition...